Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | HPGD | P15428 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545779 | 0.86 | MEN1 (0.73) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3545541 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3539969 | 0.83 | KDM4E (0.79) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2840402 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3540363 | 0.81 | KDM4E (0.72) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL31485746 | 0.80 | MEN1 (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL15864268 | 0.80 | KDM4E (0.70) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL28654740 | 0.80 | PTGS2 (0.85) | KDM4EALDH1A1HPGDMAPTTSHR | |
| SCHEMBL4792158 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4792623 | 0.77 | ALOX5 (0.77) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALDH1A1 189/4885HPGD 584/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALDH1A1 189/4885HPGD 584/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALDH1A1 189/4885HPGD 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.